N. Anthony Coles, Director at Cerevel Therapeutics Holdings, Inc. (CERE), sold 45,648 shares at $25.13 ($1.1M) on 2023-11-14, disclosed to the SEC on 2023-11-16.
Open-market sale of $1.1M CERE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.13 | 22,824 | $574K | 50.0% |
| 2 | $25.13 | 22,824 | $574K | 50.0% |
| Total | $25.13 avg | 45,648 | $1.1M | 100% |
| Filing → |
| CERE | SELL | 2024-05-14 | $2.1M | — | Filing → |
| CERE | SELL | 2024-04-03 | $2.1M | — | Filing → |
| CERE | SELL | 2024-03-06 | $2.1M | — | Filing → |